

***CURRICULUM VITAE***  
***TOMMASO CORVASCE, M.D.***

**RESUMEN**

**BIOGRAPHICAL DATA**

Place of birth: Barletta, Italy  
Date of birth: February 4, 1965  
Citizenship: Italian  
Address: (home) P.zza F. di Svevia 19, Barletta,  
70051 Italy  
Tel. (39-883) 348389  
Cell. (39-329) 6271775

(work) Chair of Urology  
University of Foggia  
Viale L. Pinto 1  
Foggia 71100 Italy  
Tel. (39-881) 732111  
E-mail: uroandros@hotmail.com

**EDUCATION**

1983 Commercial School, Istituto "Cassandro",  
Bari, Italy. Final score 60/60.

1994 University of Bari School of Medicine, Bari, Italy  
Final score: 110/110 .

1995-2000 **School of Specialization in Urological Surgery**  
University of Bari School of Medicine, Bari, Italy.  
Final score: 50/50 cum laude.  
(Prof. F.P. Selvaggi, Prof. A. Traficante)

**PROFESSIONAL EXPERIENCE**

1994 Residency in Urology, Division of Urology  
University of Bari, Bari, Italy.

2000 - 2004            Consultant Urologist of the Department of Urology  
Matera Hospital, Matera, Italy

2005 -                 Residency in Urology, Division of Urology  
University of Foggia, Bari, Italy

### **LICENSURE**

2000                    Italian State Board of Medicine

### **MEMBERSHIP IN PROFESSIONAL AND SCIENTIFIC SOCIETIES**

2001                    Italian Society of Andrology

2002                    European Association of Urology

### **TRIALS CLINIC PRINCIPAL INVESTIGATOR**

1) A randomized double blind, placebo controlled study to evaluate the efficacy and safety of Tamsulosin oral controlled absorption system (TOCAS) 0.4 and 0.8 mg tablets once daily, tamsulosin modified release 0.4 mg capsules (OMNIC) once daily and placebo in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO), formerly referred to as symptomatic benign prostatic hyperplasia (BPH); 2002

2) Registro italiano del Tromboembolismo venoso in Chirurgia oncologica (ARISTOS ITALFARMACO) 2002

3) A National, multicentre, open label, flexible dose, twelve week treatment to assess the efficacy and safety of 5 mg and 20 mg 38-9456, a Phosphodiesterase Type V inhibitor, in the treatment of male patients with erectile dysfunction. 2003

*Tommaso Corvasce, MD, Urologist*